cell immunotherapy

Oncology

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) could disrupt this shield.

Events

Partner Content

Achieving Standardization & Operational Excellence in Vein-to-Vein Supply

News

Novartis saw sales grow 3% in the second quarter, returning to growth after a 1% fall in the first quarter caused by generic competition to Entresto.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.